We previously demonstrated that USP22 contributes cisplatin chemotherapy resistance, and knockdown of USP22 sensitized lung cancer cells to cisplatin [28, 38], while a previous study found that USP7-silenced A549 cells had enhanced sensitivity to paclitaxel and docetaxel, but there was no significant change in sensitivity toward carboplatin and cisplatin [53]. Here, USP22 is linked to lung carcinoma.